AI Article Synopsis
- Preterm neonates often receive platelet transfusions for severe thrombocytopenia, despite a lack of proven benefits.
- There is significant variability in platelet transfusion practices among different regions and countries, largely relying on historical methods rather than solid evidence.
- Understanding the potential harm from transfusions is crucial for neonates, who may receive blood products throughout their lifetime, highlighting the need for more research in this area.
Article Abstract
Preterm neonates with severe thrombocytopenia are frequently prescribed prophylactic platelet transfusions despite no evidence of benefit. Neonatal platelet transfusion practice varies, both nationally and internationally. Volumes and rates of transfusion in neonatology are based on historic precedent and lack an evidence base. The etiology of harm from platelet transfusions is poorly understood. Neonates are expected to be the longest surviving recipients of blood produce transfusions, and so avoiding transfusion associated harm is critical in this cohort. This article reviews the evidence for and against platelet transfusion in the neonate and identifies areas of future potential neonatal platelet transfusion research.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.tmrv.2021.06.003 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!